The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ruxolitinib in combination with belumosudil for patients with treatment-refractory cGvHD
|
Treatment for patients with cGvHD beyond second-line therapy typically includes multiple agents with the aim of tapering systemic steroids.1 Both ruxolitinib and belumosudil are effective therapies that allow steroid tapering; however, data on the use of these therapies in combination are limited.1 A single-center, retrospective analysis assessed the safety and efficacy of ruxolitinib plus belumosudil in 20 treatment-refractory patients with cGvHD.1 Results from this analysis were published in Leukemia & Lymphoma by Caputo et al.1 |
| Key learnings |
| The ORR was 55%, with CR, PR, and initial PR then progression rates of 5%, 35%, and 15%, respectively. |
| Ruxolitinib plus belumosudil facilitated immunosuppressive agent tapering or discontinuation in all responders, highlighting its potential as a steroid-sparing option in refractory cGvHD management. |
| Treatment was well tolerated, with no discontinuations due to toxicity, indicating a favorable safety profile. Grade ≥3 pneumonia and viral URI were observed in 20% and 10% of patients, respectively, and there were no patients with CMV or EBV requiring treatment. |
| The combination of ruxolitinib and belumosudil was well-tolerated, delayed the need for alternative therapies, and facilitated the tapering of immunosuppressive therapies. Responses were observed in patients with progression after monotherapy with both agents, suggesting a potential synergistic effect. |
Abbreviations: cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; CR, complete response; EBV, Epstein-Barr virus; ORR, overall response rate; PR, partial response; URI, upper respiratory infection.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
